sinu
allergi
health
partnership
consult
repres
center
diseas
control
prevent
cdc
food
drug
administr
fda
individu
field
infecti
diseas
pediatr
infecti
diseas
microbiolog
clinic
pharmaci
clinic
pharmacolog
develop
guidelin
educ
tool
healthcar
provid
involv
treat
patient
acut
bacteri
rhinosinusti
abr
sever
problem
attempt
address
process
write
document
diagnosi
bacteri
sinus
made
frequent
patient
viral
ill
day
durat
inappropri
label
bacteri
diseas
therefor
patient
prescrib
antibiot
ineffect
viral
pathogen
also
risk
lead
develop
andor
increas
resist
variou
bacteria
includ
pneumonia
anoth
problem
frequent
encount
bacteri
infect
antibiot
frequent
use
without
regard
understand
efficaci
typic
bacteri
caus
abr
littl
logic
exist
patient
abr
first
prescrib
tmpsmx
switch
cefaclor
symptom
improv
subsequ
prescrib
azithromycin
still
improv
agent
exampl
provid
adequ
empir
treatment
pneumonia
h
influenza
major
bacteri
pathogen
abr
paper
reader
taken
stepbystep
approach
abr
terminolog
incid
definit
abr
present
variou
diagnost
modal
review
rather
creat
list
antibiot
numer
factor
eg
microbiolog
abr
pharmaco
sinu
allergi
partnership
notforprofit
organ
creat
joint
effort
american
academi
otolaryng
allergi
american
academi
otolaryngologyhead
neck
surgeri
american
rhinolog
societi
sinu
allergi
health
partnership
dynamicpharmacokinet
principl
featur
common
oral
antibiot
resist
mechan
bacteri
pathogen
result
surveil
studi
focus
preval
resist
pathogen
assist
select
antimicrobi
agent
discuss
inform
conjunct
mathemat
model
analyz
treatment
outcom
lead
develop
ration
treatment
guidelin
assist
clinician
provid
optim
treatment
patient
hope
guidelin
part
nation
intern
effort
coordin
cdc
aim
educ
health
care
provid
patient
abus
overus
antibiot
misus
antibiot
replac
spend
time
talk
examin
patient
teach
patient
andor
patient
famili
differ
viral
bacteri
infect
reli
pharmaceut
industri
develop
new
drug
organ
becom
resist
rather
must
decreas
unnecessari
antimicrobi
use
mean
reduc
spread
resist
believ
research
necessari
develop
better
method
diagnos
abr
explor
clinic
applic
antibiot
recommend
present
document
monitor
level
bacteri
resistanceespeci
pneumonia
h
influenza
unit
state
averag
child
averag
adult
acut
viral
respiratori
ill
per
year
patient
ct
scan
evid
paranas
sinu
involv
consid
selflimit
viral
rhinosinus
vr
bacteri
infect
also
refer
abr
complic
roughli
vr
estim
billion
case
vr
occur
annual
unit
state
assum
bacteri
complic
rate
million
case
vr
complic
abr
annual
addit
public
health
implic
rhinosinus
consider
econom
impact
primari
diagnosi
rhinosinus
led
expenditur
approxim
billion
unit
state
nation
center
health
statist
conduct
sampl
survey
officebas
physician
unit
state
call
namc
data
namc
namc
namc
namc
namc
indic
increas
number
adult
visit
physician
offic
result
diagnosi
acut
chronic
rhinosinus
accord
namc
data
sinus
fifth
common
diagnosi
antibiot
prescrib
diagnosi
rhinosinus
made
antibiot
prescript
written
respect
total
number
antibiot
prescript
increas
throughout
last
decad
resist
antimicrobi
agent
among
bacteri
respiratori
pathogen
emerg
signific
public
health
issu
antibiot
use
causal
relat
develop
spread
bacteri
drug
resist
strategi
result
prudent
ration
antimicrobi
use
increasingli
import
rhinosinus
two
scenario
antibiot
prescrib
particular
concern
first
frequent
treatment
uncompl
vr
antimicrobi
second
select
antimicrobi
agent
without
document
efficaci
goal
panel
develop
guidelin
judici
use
antibiot
treatment
abr
american
academi
otolaryngologyhead
neck
surgeri
develop
work
definit
sinus
clarifi
commun
among
provid
research
sinus
usual
preced
rhiniti
rare
occur
without
concurr
rhiniti
decid
sinus
best
describ
rhinosinus
term
acut
subacut
recurr
acut
chronic
rhinosinus
review
terminolog
subsequ
adopt
agenc
healthcar
research
qualiti
develop
document
diagnosi
treatment
abr
pathophysiolog
characterist
abr
abr
often
preced
viral
uri
allergi
trauma
environment
factor
lead
inflamm
nose
paranas
sinus
may
also
predispos
individu
abr
approxim
common
cold
caus
human
rhinoviru
virus
caus
cold
includ
coronaviru
influenza
b
virus
parainfluenza
viru
respiratori
syncyti
viru
adenoviru
enteroviru
human
rhinoviru
coronaviru
caus
major
epitheli
damag
influenza
viru
adenoviru
damag
nasal
epithelium
infect
occur
earli
fall
earli
spring
season
human
rhinoviru
enter
nose
attach
rhinoviru
receptor
epitheli
cell
posterior
nasopharynx
subsequ
activ
inflammatori
pathway
parasympathet
nervou
system
gener
symptom
sign
viral
rhiniti
viral
sinus
studi
patient
gwaltney
et
al
adult
acut
onset
uri
symptom
demonstr
inflamm
within
nose
viscou
secret
sometim
bubbl
sinus
ct
scan
week
without
antibiot
therapi
repeat
ct
scan
subject
reveal
either
disappear
mark
improv
previous
identifi
abnorm
fever
myalgia
pharyng
associ
viral
uri
tend
resolv
day
nasal
congest
cough
may
persist
second
third
week
figur
fever
alon
day
suggest
abr
approxim
adult
patient
viral
uri
secondari
bacteri
infect
paranas
sinus
develop
caus
secondari
bacteri
invas
sinus
unknown
combin
factor
nose
blow
local
system
immun
virul
viru
colon
nasopharynx
potenti
bacteri
pathogen
eg
pneumonia
variou
environment
factor
may
lead
condit
conduc
bacteri
entri
growth
sinus
differenti
viral
uri
abr
challeng
children
adult
averag
child
viral
uri
per
year
potenti
inappropri
antibiot
use
high
mean
durat
viral
uri
rang
day
children
home
care
day
children
year
old
day
care
upper
respiratori
tract
symptom
may
howev
last
day
children
home
care
children
fever
myalgia
sneez
sore
throat
cough
rhinorrhea
common
persist
signific
proport
patient
persist
last
symptom
entir
consist
uncompl
rhinoviru
infect
day
care
case
children
day
care
like
protract
respiratori
symptom
variabl
percentag
children
uri
symptom
prescrib
antibiot
clinic
diagnosi
patient
common
cold
usual
report
combin
follow
symptom
sneez
rhinorrhea
nasal
congest
hyposmia
anosmia
facial
pressur
postnas
drip
sore
throat
cough
ear
full
fever
myalgia
contrari
popular
belief
chang
color
characterist
nasal
discharg
specif
sign
bacteri
infect
day
viral
infect
mucopurul
nasal
secret
may
occur
influx
neutrophil
point
viral
uri
becom
superinfect
pathogen
bacteria
determin
repeat
sinu
aspir
studi
sinu
aspir
studi
adult
demonstr
signific
bacteri
growth
approxim
patient
uri
symptom
last
least
day
risk
bacteri
superinfect
occur
greater
ill
better
wors
day
may
case
fall
norm
typic
progress
specif
find
suggest
bacteri
infect
fever
facial
erythema
swell
sever
pain
practic
clinician
need
reli
clinic
judgment
use
guidelin
gener
howev
diagnosi
abr
may
made
adult
children
viral
uri
better
day
worsen
day
accompani
follow
symptom
nasal
drainag
nasal
congest
facial
pressur
pain
especi
unilater
focus
region
particular
sinu
postnas
drainag
hyposmiaanosmia
fever
cough
fatigu
maxillari
dental
pain
ear
pressureful
tabl
physic
examin
provid
limit
inform
extrem
use
diagnosi
abr
unlik
acut
otiti
media
tympan
membran
middl
ear
space
readili
avail
direct
examin
paranas
sinus
hidden
deep
within
skull
anterior
rhinoscopi
without
topic
decongest
allow
examin
mucosa
inferior
turbin
secret
within
anterior
nose
orient
nasal
septum
fiberopt
endoscopi
allow
visual
middl
meatu
direct
cultur
purul
region
may
correl
cultur
maxillari
sinu
aspir
endoscopi
howev
necessari
uncompl
case
abr
transillumin
reproduc
rate
assess
diseas
within
maxillari
sinus
frontal
sinus
respect
differenti
bacteri
viral
infect
bmode
ultrasound
replac
amod
ultrasound
diagnosi
diseas
within
paranas
sinus
howev
maxillari
sinu
adequ
assess
bmode
ultrasound
limit
util
studi
correl
ct
scan
bmode
ultrasound
find
demonstr
sensit
ultrasound
maxillari
sinus
frontal
sinus
ethmoid
compar
clinic
evalu
sensit
bmode
ultrasound
specif
ultrasound
techniquesensit
may
mark
variat
reliabl
inform
provid
ultrasound
distinguish
viral
bacteri
rhinosinus
plain
film
radiograph
primarili
reveal
patholog
find
maxillari
frontal
sinus
wherea
ethmoid
poorli
visual
addit
plain
radiograph
imprecis
determin
extent
diseas
metaanalysi
studi
demonstr
posit
plain
film
radiograph
moder
sensit
specif
compar
maxillari
sinu
punctur
neg
radiograph
diagnost
valu
either
neg
clinic
examin
ultrasound
ct
scan
clearli
demonstr
abnorm
within
sinus
howev
previous
note
abnorm
frequent
found
ct
scan
patient
viral
respiratori
diseas
mri
scan
without
expos
patient
ioniz
radiat
distinctli
reveal
mucos
thicken
fluid
within
paranas
sinus
patient
maxillari
sinus
serial
mri
scan
demonstr
mucos
thicken
persist
week
ct
mri
scan
indic
uncompl
case
abr
appropri
case
complic
seriou
problem
may
suspect
punctur
maxillari
sinu
canin
fossa
inferior
meatu
provid
materi
may
cultur
identifi
bacteri
isol
technic
expertis
requir
minim
complic
somewhat
uncomfort
patient
maxillari
sinu
punctur
routin
use
case
suspect
abr
usual
reserv
research
set
patient
unrespons
complic
infect
bacteria
broadli
classifi
group
base
cell
wall
composit
morpholog
characterist
metabol
requir
cell
wall
import
determin
inher
suscept
resist
bacterium
mani
antimicrobi
agent
consist
primarili
protein
lipid
peptidoglycan
layer
peptidoglycan
layer
compos
oligosaccharid
chain
crosslink
short
peptid
serv
major
structur
compon
maintain
cell
wall
integr
although
gramposit
gramneg
bacteria
share
mani
common
structur
element
cell
wall
organ
content
element
vari
two
bacteri
class
figur
cell
wall
gramposit
bacteria
consist
almost
entir
thick
peptidoglycan
layer
fuse
outsid
cytoplasm
membran
gramneg
bacteria
howev
cell
wall
compos
hydrophob
lipopolysaccharid
capsul
surround
lipoproteinphospholipid
membran
contain
small
channel
call
porin
thin
peptidoglycan
layer
lie
outer
membran
inner
cytoplasm
membran
two
biolog
layer
separ
periplasm
space
space
import
site
degrad
antibiot
drug
inactiv
enzym
gramneg
bacteria
penicillinbind
protein
pbp
enzym
essenti
cell
wall
synthesi
locat
cytoplasm
membran
pbp
found
gramneg
gramposit
organ
alter
pbp
decreas
affin
blactam
identifi
varieti
organ
common
bacteri
isol
recov
maxillari
sinus
patient
abr
pneumonia
h
influenza
streptococc
speci
catarrhali
review
sinu
aspir
studi
perform
adult
abr
shown
pneumonia
isol
approxim
h
influenza
catarrhali
aspir
figur
children
abr
pneumonia
isol
approxim
wherea
h
influenza
catarrhali
recov
aspir
streptococcu
pyogen
anaerob
account
figur
bacteri
isol
found
patient
abr
includ
aureu
anaerob
streptococci
gramposit
catalaseneg
facult
anaerob
spheric
bacteria
typic
seen
pair
chain
nutrit
fastidi
requir
complex
media
contain
blood
serum
growth
growth
often
enhanc
carbon
dioxideenrich
atmo
phere
pneumonia
belong
ahemolyt
group
streptococci
distinguish
viridan
group
occurr
pair
requir
carbon
dioxid
primari
isol
autolys
presenc
bile
salt
bile
solubl
optochin
inhibit
optochincontain
disk
pneumococci
usual
encapsul
capsular
polysaccharid
use
serolog
classif
antigen
distinct
capsular
serotyp
distinct
serogroup
describ
serotyp
common
antigen
group
togeth
serogroup
account
design
exampl
serogroup
sequenti
colon
nasopharynx
pneumococci
differ
serotyp
occur
start
soon
birth
strain
persist
month
point
preval
survey
shown
two
third
children
one
third
adult
nasopharyng
colon
pneumococci
preval
highest
winter
respiratori
viral
infect
children
demonstr
colon
year
age
frequent
serotyp
serogroup
colon
infant
pneumococci
also
shown
high
frequenc
genet
recombin
strain
carri
nasopharynx
may
frequent
chang
serotyp
incid
diseas
vari
serotyp
infect
caus
serotyp
serogroup
highest
children
wherea
caus
serotyp
highest
adult
serotyp
serogroup
tend
caus
diseas
similar
frequenc
age
group
furthermor
found
serogroup
account
approxim
infect
seven
serotyp
order
decreas
frequenc
account
isol
blood
cerebrospin
fluid
middl
ear
sourc
children
unit
state
present
newli
avail
conjug
pneumococc
vaccin
antimicrobi
resist
seen
mainli
serotyp
serotyp
also
present
newli
avail
conjug
pneumococc
vaccin
serotyp
rare
antibioticresist
gene
reason
differ
unknown
organ
belong
genu
haemophilu
consist
small
pleomorph
facult
anaerob
gramneg
bacilli
speci
complex
nutrit
requir
growth
enhanc
carbon
dioxideenrich
atmospher
h
influenza
character
requir
hemin
x
factor
nad
v
factor
strain
h
influenza
may
either
encapsul
unencapsul
encapsul
strain
includ
serotyp
serotyp
f
h
influenza
type
b
lead
caus
bacteremia
mening
children
introduct
effect
vaccin
serotyp
howev
nontyp
strain
typic
caus
uri
otiti
media
sinus
acut
exacerb
chronic
bronchiti
accordingli
occurr
infect
affect
use
type
b
vaccin
strain
nontyp
h
influenza
sequenti
colon
nasopharynx
process
start
infanc
year
age
children
demonstr
colon
strain
carri
month
mean
month
product
h
influenzaespecif
iga
result
erad
carriag
strain
follow
acquisit
new
strain
differ
surfac
protein
speci
consist
aerob
oxidaseposit
gramneg
diplococci
much
less
fastidi
growth
requir
either
streptococci
haemophilu
speci
grow
simpl
media
without
blood
serum
case
pneumonia
h
influenza
catarrhali
colon
nasopharynx
earli
childhood
children
demonstr
colon
year
age
child
sequenti
colon
differ
strain
catarrhali
otitispron
children
frequent
colon
normal
children
start
soon
birth
nasopharynx
colon
flora
viridan
streptococci
corynebacterium
speci
neisseria
speci
anaerob
colon
respiratori
pathogen
occur
intermitt
discuss
month
age
children
colon
least
major
respiratori
pathogen
pneumonia
h
influenza
catarrhali
colon
pathogen
increas
consider
period
viral
uri
often
result
organ
caus
bacteri
otiti
media
sinus
addit
administr
antimicrobi
increas
carriag
antimicrobialresist
strain
bacteri
pathogen
adult
also
colon
nasopharynx
durat
carriag
shorter
children
numer
method
may
use
assess
vitro
activ
antibiot
test
minim
inhibitori
concentr
mic
minim
bactericid
concentr
mbc
minimum
lethal
concentr
timekil
test
valid
method
assess
antimicrobi
activ
howev
import
understand
use
limit
test
antimicrobi
activ
commonli
evalu
determin
mic
particular
antibiot
specif
bacteri
strain
figur
therefor
mic
report
mgml
true
inhibitori
concentr
somewher
two
term
use
mic
mic
inhibit
isol
test
mic
mic
inhibit
isol
test
extrem
import
rememb
mic
vitro
characterist
antimicrobi
determin
strictli
adher
condit
environment
condit
site
infect
rare
correspond
vitro
suscept
test
condit
effect
element
oxygen
tension
ph
protein
bind
activ
antimicrobi
interest
need
consid
exampl
low
ph
significantli
detriment
effect
activ
macrolid
therefor
even
organ
appear
suscept
vitro
clinic
failur
may
occur
vivo
condit
detract
activ
drug
similarli
host
factor
may
actual
serv
improv
vivo
activ
antimicrobi
macrophag
opson
factor
complement
may
act
synergist
antibiot
thu
provid
enhanc
antibacteri
activ
would
predict
vitro
addit
mani
bacteri
infect
resolv
spontan
without
use
antimicrobi
agent
mic
defin
amount
antimicrobi
necessari
inhibit
growth
microb
contrast
mbc
provid
inform
regard
concentr
drug
requir
kill
organ
mbc
like
mic
vitro
test
subject
similar
limit
relat
clinic
effect
mbc
calcul
determin
chang
inocula
bacteria
incub
presenc
vari
drug
concentr
time
defin
lowest
drug
concentr
result
reduct
viabl
count
hour
compar
initi
inoculum
mbc
valu
gener
rang
doubl
dilut
higher
mic
valu
mic
better
standard
less
costli
less
labor
intens
use
often
mbc
howev
mbc
much
higher
mic
unless
drug
known
bacteriostat
organ
said
display
toler
antimicrobi
primari
mechan
antimicrobi
resist
express
product
antibioticinactiv
enzym
alter
antimicrobi
target
site
alter
bacteri
influxefflux
process
bacteria
may
exhibit
differ
mechan
antibioticinactiv
enzym
enzym
identifi
result
inactiv
sever
class
antimicrobi
includ
macrolid
lincosamid
tetracyclin
howev
familiar
class
antibioticinactiv
enzym
enzym
hydrolyz
amid
bond
ring
result
inactiv
isol
numer
gramposit
gramneg
bacteria
product
either
constitut
requir
antibiot
exposur
induc
product
stimul
presenc
antimicrobi
effort
overcom
effect
resist
new
antibiot
resist
hydrolysi
well
inhibitor
develop
clavulan
acid
broadspectrum
irrevers
inhibitor
staphylococci
mani
gramneg
bacteria
clavulan
acid
destroy
process
inhibit
often
describ
suicid
inhibitor
combin
amoxicillinclavulan
acid
use
treatment
mani
bacteria
includ
aureu
h
influenza
catarrhali
inhibitor
includ
tazobactam
sulbactam
import
note
inhibitor
serv
increas
amount
activ
compound
reach
target
site
avail
exert
activ
otherwis
suscept
bacteria
therefor
bacteria
inher
suscept
absenc
addit
inhibitor
make
organ
suscept
drug
alter
target
site
target
bind
site
antimicrobi
compon
bacterium
antimicrobi
must
attach
produc
desir
effect
chang
occur
configur
bind
site
affin
antimicrobi
target
site
may
significantli
decreas
result
action
drug
bacterium
may
significantli
lessen
elimin
target
reduc
affin
antimicrobi
bind
describ
macrolid
quinolon
pneumonia
resist
develop
stepwis
alter
pbp
lead
decreas
bind
affin
blactam
variou
degre
resist
may
develop
numer
chang
occur
alter
pbp
affin
pbp
alter
respons
resist
pneumonia
fluoroquinolon
resist
occur
result
alter
bind
site
target
site
alter
gener
occur
fashion
pneumonia
instanc
initi
alter
parc
gene
encod
topoisomeras
iv
result
lowlevel
quinolon
resist
second
mutat
gyra
gene
encod
gyr
subunit
dna
gyras
result
express
highlevel
quinolon
resist
although
crossresist
commonli
occur
among
fluoroquinolon
newest
agent
often
remain
activ
strain
becom
resist
older
agent
differ
fluoroquinolon
like
target
interact
differ
region
dna
gyras
topoisomeras
molecul
varieti
mutat
gene
encod
enzym
confer
fluoroquinolon
resist
resist
tmpsulfonamid
combin
also
primarili
result
alter
target
bind
site
eg
dihydroptero
synthas
dihydrofol
reductas
antimicrobi
exert
desir
biolog
effect
must
first
penetr
sever
protect
barrier
microb
barrier
includ
inner
membran
cell
wall
outer
membran
gramneg
bacteria
help
cell
regul
flow
substanc
lipophil
substanc
capabl
passiv
diffus
across
membran
howev
passag
hydrophil
materi
may
facilit
waterfil
porin
channel
porin
one
mechan
antimicrobi
may
travers
hydrophob
barrier
antimicrobi
may
also
enter
cell
proteinmedi
transport
chang
occur
either
number
configur
porin
channel
transport
protein
abil
antimicrobi
reach
activ
site
may
greatli
reduc
anoth
structur
chang
significantli
reduc
concentr
antibiot
target
site
activ
antimicrobi
efflux
pump
import
mechan
resist
regul
activ
energydepend
protein
activ
pump
antimicrobi
cell
mechan
macrolid
resist
macrolid
resist
result
destruct
drugmodifi
enzym
alter
ribosom
bind
site
decreas
cellular
permeabl
two
import
gene
respons
macrolid
resist
erm
ribosom
methylas
mef
macrolidespecif
efflux
mechan
among
isol
pneumonia
resist
result
frequent
target
site
modif
methyl
alter
efflux
pump
mef
efflux
mechan
confer
moder
degre
resist
compar
high
level
resist
seen
strain
possess
methylas
mechan
efflux
mechan
gener
common
unit
state
rel
uncommon
part
world
ribosom
methylas
mediat
efflux
macrolid
resist
confer
crossresist
clindamycin
macrolid
use
therefor
like
caus
measur
increas
pneumonia
resist
macrolid
clindamycin
isol
pneumonia
penicillin
mic
defin
suscept
intermedi
strain
penicillin
mic
wherea
resist
isol
pneumonia
penicillin
mic
two
group
often
refer
penicillin
nonsuscept
tabl
drsp
term
use
describ
isol
pneumonia
penicillin
mic
resist
class
antibiot
multidrugresist
pneumonia
defin
organ
resist
class
antibiot
increas
preval
isol
pneumonia
penicillin
nonsuscept
problem
unit
state
figur
late
earli
penicillin
nonsuscept
pneumonia
becam
major
concern
one
recent
sourc
resist
data
isol
pneumonia
come
us
compon
alexand
project
surveil
studi
collect
respiratori
tract
isol
communitybas
physician
throughout
unit
state
us
compon
alexand
project
demonstr
pneumonia
isol
penicillinintermedi
penicillinresist
respect
preval
penicillin
resist
significantli
higher
middl
ear
sinu
isol
strain
recov
site
cdc
surveil
studi
invas
ie
blood
cerebrospin
fluid
pneumonia
isol
hospit
clinic
laboratori
demonstr
isol
penicillinintermedi
penicillinresist
respect
dispar
preval
penicillin
nonsuscept
pneumonia
isol
studi
may
relat
isol
us
compon
alexand
project
like
origin
patient
respond
treatment
true
preval
isol
pneumonia
resist
ofloxacin
drsp
isol
preval
children
younger
year
age
especi
prior
antibiot
exposur
otiti
media
drsp
associ
bacteriolog
treatment
failur
sever
oral
cephalosporin
macrolid
product
primari
mechan
resist
isol
h
influenza
catarrhali
us
preval
produc
isol
h
influenza
increas
past
year
current
stabl
approxim
figur
us
compon
alexand
project
report
preval
product
isol
h
influenza
sinu
specimen
adult
age
year
tend
higher
preval
isol
h
influenza
current
avail
macrolid
includ
azithromycin
clar
crossresist
penicillin
drug
class
pneumonia
resist
pneumonia
penicillin
rise
resist
antibiot
also
increas
ithromycin
intrins
poor
baselin
activ
isol
h
influenza
otiti
media
doubl
tap
erad
studi
show
agent
h
influenza
erad
rate
compar
placebo
us
compon
alexand
project
isol
h
influenza
tmpsmxresist
none
fluoroquinoloneresist
amoxicillinclavulan
cefixim
cefpodoxim
proxetil
effect
h
influenza
outpati
us
preval
isol
catarrhali
isol
catarrhali
resist
tmpsmx
isol
catarrhali
suscept
amoxicillinclavulan
cefixim
fluoroquinolon
macrolidesazalid
extens
use
antibiot
may
associ
develop
spread
resist
microorgan
nasopharyng
carriag
resist
isol
pneumonia
relat
recent
antimicrobi
use
well
live
area
high
volum
antibiot
use
preval
isol
catarrhali
found
grow
increas
consumpt
cephalosporin
finland
consumpt
erythromycin
relat
increas
preval
erythromycinresist
group
streptococci
howev
steadi
statist
signific
declin
macrolid
resist
group
streptococci
occur
reduc
use
macrolid
antibiot
year
data
reinforc
rational
judici
antibiot
use
antimicrobi
class
includ
fluoroquinolon
macrolid
azalid
lincosamid
tetracyclin
sulfonamidestrimethoprim
class
antimicrobi
includ
broad
rang
compound
significantli
differ
spectra
activ
agent
share
common
structur
compon
ring
exert
antibacteri
action
inhibit
cell
wall
synthesi
action
accomplish
bind
antimicrobi
variou
pbp
cell
wall
differ
pbp
penicillinsuscept
pneumonia
oral
avail
agent
includ
penicillin
without
inhibitor
compound
cephalosporin
cephalosporin
modifi
broaden
spectrum
antimicrobi
activ
enhanc
pharmacokinet
properti
circumv
problem
drug
degrad
amoxicillin
amoxil
less
potent
better
absorb
deriv
ampicillin
amoxicillin
rel
safe
well
toler
activ
limit
destruct
produc
strain
h
influenza
catarrhali
staphylococcu
gramneg
oral
anaerob
speci
given
intrins
activ
excel
bioavail
amoxicillin
gener
consid
activ
oral
streptococci
includ
pneumococci
resist
penicillin
isol
pneumonia
rel
may
overcom
case
use
higher
dose
amoxicillin
although
typic
adult
amoxicillin
dose
gday
typic
pediatr
amoxicillin
dose
mgkg
per
day
time
higher
daili
dose
may
necessari
erad
isol
pneumonia
even
high
dose
may
suffici
treat
highli
penicillinresist
pneumonia
strain
highdos
amoxicillin
approv
fda
systemat
evalu
safeti
profil
yet
well
defin
intrins
activ
amoxicillin
strain
h
influenza
fair
good
amoxicillin
time
less
potent
thirdgener
cephalosporin
eg
cefixim
cefpodoxim
proxetil
failur
may
expect
infect
caus
strain
h
influenza
treat
standard
dose
amoxicillin
highdos
amoxicillin
may
allevi
problem
howev
amoxicillin
ineffect
strain
amoxicillinclavulan
augmentin
resist
agent
among
isol
pneumonia
involv
product
addit
clavulan
amoxicillin
increas
activ
drsp
clavulan
howev
enhanc
amoxicillin
activ
strain
h
influenza
catarrhali
staphylococci
except
methicillinresist
strain
oral
anaerob
irrevers
bind
restor
activ
amoxicillin
addit
clavulan
appear
drive
forc
toward
develop
resist
given
time
day
regimen
broadspectrum
associ
high
incid
gastrointestin
side
effect
compar
altern
problem
significantli
decreas
twice
day
dose
clavulan
dose
howev
exceed
approxim
mgkg
per
day
diarrhea
becom
problem
cefuroxim
axetil
ceftin
parenter
cefuroxim
sodium
longestablish
histori
treatment
moder
sever
lower
respiratori
infect
caus
h
influenza
pneumonia
oral
formul
cefuroxim
axetil
introduc
demonstr
good
potenc
efficaci
sideeffect
profil
limit
activ
pneumonia
high
level
penicillin
resist
maintain
activ
penicillinintermedi
strain
cefuroxim
axetil
effect
strain
h
influenza
cefpodoxim
proxetil
vantin
structur
analog
parenter
agent
ceftriaxon
cefpodoxim
proxetil
much
activ
respiratori
pathogen
potent
activ
h
influenza
strain
activ
compar
cefuroxim
axetil
cefprozil
penicillinsuscept
pneumonia
isol
reason
activ
penicillinintermedi
pneumonia
cefprozil
cefzil
among
besttast
toler
broadspectrum
oral
cefprozil
activ
pneumococcu
compar
cefuroxim
axetil
cefpodoxim
proxetil
howev
markedli
less
activ
h
influenza
cefixim
suprax
prototyp
oral
thirdgener
oral
cephalosporin
cefixim
potent
activ
h
influenza
provid
weak
gramposit
coverag
includ
pneumonia
cefixim
activ
staphylococci
may
occasion
fail
even
penicillinsuscept
pneumococci
clinic
signific
activ
drsp
cefaclor
ceclor
cefaclor
poor
activ
h
influenza
fair
activ
penicillinsuscept
pneumococci
activ
drsp
therefor
cefaclor
poor
overal
efficaci
bacteri
respiratori
tract
pathogen
loracarbef
lorabid
loracarbef
compar
cefaclor
activ
pathogen
respiratori
tract
infect
fluoroquinolon
gatifloxacin
tequin
levofloxacin
levaquin
moxifloxacin
avelox
topoisomeras
vital
enzym
involv
mainten
topolog
supercoil
dna
within
bacteria
two
dna
topoisomeras
bacteria
topoisomeras
ii
also
known
dna
gyras
involv
decoil
dna
replic
topoisomeras
iv
involv
separ
dna
strand
fluoroquinolon
exert
bactericid
activ
bind
dna
gyras
topoisomeras
iv
imped
format
supercoil
dna
inhibit
relax
supercoil
dna
promot
doublestrand
dna
breakag
gener
dna
gyras
appear
target
molecul
gramneg
bacteria
topoisomeras
iv
appear
target
gramposit
pathogen
newer
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
remark
potenc
h
influenza
catarrhali
unlik
ciprofloxacin
strong
potenc
pneumonia
although
gastrointestin
absorpt
agent
inhibit
coadministr
food
supplement
certain
multival
cation
magnesium
aluminum
iron
calcium
gener
lack
phototox
seen
quinolon
major
concern
surround
fluoroquinolon
select
class
resist
organ
gramneg
enter
especi
pseudomona
aeruginosa
staphylococci
pneumococci
toxic
known
unrecogn
also
issu
particularli
newli
approv
agent
fluoroquinolon
current
approv
use
children
macrolidesazalid
erythromycin
clarithromycin
biaxin
azithromycin
zithromax
macrolid
includ
agent
erythromycin
clarithromycin
azithromycin
azalid
structur
similar
macrolid
agent
activ
gramposit
gramneg
bacteria
antimicrobi
inhibit
rnadepend
protein
synthesi
revers
bind
subunit
bacteri
ribosom
although
gener
consid
bacteriostat
studi
demonstr
bactericid
activ
presenc
high
macrolid
concentr
macrolid
exhibit
better
antibacteri
activ
environ
neutral
basic
ph
physiochem
characterist
caus
fact
low
ph
macrolid
becom
posit
charg
readili
pass
biolog
membran
effect
pronounc
azithromycin
carri
doubl
posit
charg
low
ph
macrolid
good
activ
macrolidesuscept
pneumococci
howev
increas
rate
macrolid
resist
pneumonia
associ
signific
likelihood
clinic
failur
although
clarithromycin
azithromycin
slightli
greater
activ
h
influenza
erythromycin
avail
erad
efficaci
studi
suggest
activ
similar
margin
higher
placebo
although
controversi
creat
activ
metabolit
clarithromycin
intracellular
concentr
newer
agent
effect
ph
mic
result
none
issu
affect
forego
conclus
activ
drug
extracellular
pathogen
pneumonia
h
influenza
macrolidesazalid
activ
catarrhali
lincosamid
clindamycin
cleocin
clindamycin
primari
lincosamid
antibiot
clinic
use
similar
macrolid
clindamycin
act
bind
ribosom
subunit
suscept
bacteria
thu
suppress
protein
synthesi
clindamycin
bactericid
bacteriostat
depend
bacteri
inoculum
speci
drug
concentr
site
infect
clindamycin
use
clinic
treatment
suscept
gramposit
aerob
anaerob
well
mani
gramneg
anaerob
howev
activ
h
influenza
catarrhali
tetracyclin
doxycyclin
doryx
vibramycin
antibiot
bacteriostat
inhibit
bacteri
growth
inhibit
rnadepend
protein
synthesi
revers
bind
ribosom
subunit
deriv
tetracyclin
doxycyclin
adequ
activ
penicillinsuscept
pneumococci
like
oral
likelihood
resist
doxycyclin
rise
pneumococc
strain
exhibit
degre
penicillin
resist
doxycyclin
also
activ
catarrhali
activ
h
influenza
limit
pharmacokinet
clinician
awar
possibl
photosensit
infrequ
esophag
caustic
burn
like
tetracyclin
usag
children
younger
year
contraind
possibl
tooth
enamel
discolor
sulfonamid
tmp
trimethoprimsulfamethoxazol
bactrim
septra
sulfonamid
disrupt
bacteri
folic
acid
synthesi
inhibit
dihydroptero
synthas
result
bacteriostat
activ
tmp
pyrimidin
analog
inhibit
dihydrofol
reductas
sulfonamid
trimethoprim
block
folic
acid
synthesi
differ
site
potenti
antimicrobi
activ
produc
synergist
bacteriostat
activ
high
rate
resist
drug
present
pneumococci
h
influenza
catarrhali
intrins
resist
sulfamethoxazol
addit
agent
like
caus
skin
rash
erythema
multiform
toxic
epiderm
necrolysi
potenti
fatal
new
antibiot
new
class
antibiot
ketolid
oxazolidinon
glycylcyclin
well
antibiot
clinic
trial
time
write
review
document
recent
metaanalysi
includ
random
clinic
trial
antibiot
treatment
prescrib
abr
evalu
efficaci
antibiot
versu
placebo
n
amoxicillin
versu
antibiot
n
folat
inhibitor
versu
antibiot
n
even
though
patient
receiv
placebo
abr
symptomat
improv
cure
antibiot
significantli
reduc
treatment
failur
approxim
one
half
statist
signific
clinic
meaning
differ
cure
rate
amoxicillin
folat
inhibitor
antibiot
antibiot
versu
placebo
trial
evalu
follow
antibiot
lincomycin
penicillin
v
cyclacillin
amoxicillin
amoxicillinclavulan
doxycyclin
amoxicillin
folat
inhibitor
versu
antibiot
trial
includ
follow
antibiot
amoxicillinclavulan
azithromycin
clarithromycin
cefaclor
cefixim
cefpodoxim
proxetil
cefuroxim
axetil
minocyclin
cephalexin
tetracyclin
pivampicillin
roxithromycin
result
metaanalysi
appli
uncompl
communityacquir
case
abr
individu
trial
perform
develop
resist
current
found
pneumonia
h
influenza
catarrhali
result
metaanalysi
may
applic
current
treatment
abr
method
use
paper
evalu
antimicrobi
therapi
abr
howev
take
account
current
high
level
antibioticresist
organ
mic
mbc
commonli
use
describ
vitro
potenc
antimicrobi
agent
measur
howev
take
consider
pharmacokinet
properti
antimicrobi
agent
therefor
abil
predict
therapeut
efficaci
limit
pharmacokinet
absorpt
distribut
metabol
excret
mani
antimicrobi
well
establish
howev
disciplin
pharmacodynam
recent
emerg
pharmacodynam
describ
relat
drug
concentr
pharmacolog
effect
antibiot
describ
relat
exist
drug
concentr
bacteria
expos
variou
site
infect
bacteri
kill
evolut
scienc
augment
bodi
knowledg
antimicrobi
best
treat
infect
pharmacokinet
pharmacodynam
principl
form
scientif
basi
ration
use
antimicrobi
agent
portion
guidelin
provid
review
pharmacodynam
vivo
bacteri
kill
may
describ
function
durat
antimicrobi
drug
concentr
time
rel
mic
agent
particular
pathogen
product
pharmacokinet
paramet
drug
concentr
time
drug
exposur
dose
interv
express
area
concentrationtim
curv
auc
figur
antimicrobi
agent
thu
classifi
base
pharmacodynam
paramet
best
describ
vivo
pattern
bactericid
activ
tabl
antimicrobi
exhibit
timedepend
kill
macrolid
clindamycin
show
littl
concentrationdepend
bactericid
activ
antimicrobi
concentr
exce
critic
valu
time
mic
drug
particular
organ
kill
proce
increas
drug
concentr
increas
rate
extent
bacteri
death
antibiot
exhibit
timedepend
concentrationindepend
kill
henc
best
predictor
clinic
outcom
durat
time
concentr
drug
serum
andor
site
infect
mic
mic
bacteria
extracellular
pathogen
freedrug
concentr
serum
gener
proport
interstiti
fluid
bath
organ
therefor
proport
dose
interv
freedrug
concentr
serum
exce
antimicrobi
mic
pathogen
also
reflect
paramet
site
infect
amount
time
concentr
timedepend
antibiot
remain
mic
mic
given
bacteria
may
vari
pathogen
immunocompet
host
data
vitro
pharmacokinet
simul
anim
model
human
clinic
studi
suggest
mic
dose
interv
immunocompet
host
timedepend
antibiot
figur
relationship
mic
clinic
efficaci
evalu
patient
acut
otiti
media
caus
pneumonia
h
influenza
bacteriolog
cure
rate
observ
mic
macrolid
dose
interv
moreov
hospit
patient
communityacquir
pneumonia
differ
clinic
outcom
observ
patient
receiv
cefuroxim
sodium
mg
per
day
continu
infus
mic
compar
mg
intermitt
time
daili
estim
mic
thu
serum
concentr
present
dose
interv
may
use
determin
suscept
limit
breakpoint
organ
given
dose
regimen
addit
proport
bacteria
mic
suscept
limit
breakpoint
may
determin
tabl
summar
suscept
pneumonia
h
influenza
catarrhali
variou
antimicrobi
pkpd
breakpoint
cefaclor
cefprozil
cefuroxim
cefpodoxim
cefixim
loracarbef
macrolid
azithromycin
gatifloxacin
levofloxacin
moxifloxacin
checkmark
adequ
pharmacodynam
profil
use
convent
dose
patient
normal
renal
hepat
function
borderlin
pharmacodynam
profil
use
convent
dose
patient
normal
renal
hepat
function
macrolid
mic
dose
interv
quinolon
aucmic
ratio
h
influenza
pneumonia
amoxicillin
two
larg
vitro
suscept
pharmacodynam
studi
conduct
unit
state
first
studi
isol
pneumonia
evalu
antimicrobi
test
includ
amoxicillin
amoxicillinclavulan
cefuroxim
axetil
cefprozil
cefaclor
cefixim
loracarbef
oral
evalu
penicillinsuscept
pneumonia
isol
concentr
present
dose
interv
base
approv
dosag
regimen
exceed
mic
amoxicillin
amoxicillinclavulan
cefuroxim
axetil
cefprozil
achiev
paramet
penicillinintermedi
isol
pneumonia
penicillinresist
pneumonia
isol
amoxicillin
amoxicillinclavulan
achiev
pharmacodynam
target
percentag
pneumonia
strain
suscept
pharmacodynam
breakpoint
follow
amoxicillin
amoxicillinclavulan
cefuroxim
axetil
cefprozil
cefixim
cefaclor
loracarbef
second
vitro
suscept
pharmacodynam
studi
similarli
evalu
isol
pneumonia
penicillinsuscep
pharmacodynam
concept
time
mic
schemat
illustr
serum
pharmacokinet
profil
timedepend
oral
drug
regimen
one
dose
interv
drug
present
dose
interv
drug
b
present
approxim
dose
interv
dose
interv
therefor
infect
caus
pathogen
mic
drug
like
cure
drug
rather
drug
b
drug
b
would
howev
effect
strain
mic
less
drug
b
present
dose
interv
drug
b
two
differ
timedepend
drug
two
differ
dose
regimen
agent
suscept
oral
base
pharmacodynam
breakpoint
follow
cefixim
amoxicillinclavulan
cefuroxim
axetil
amoxicillin
cefprozil
loracarbef
cefaclor
macrolidesazalid
macrolid
eg
erythromycin
clarithromycin
azalid
eg
azithromycin
exhibit
concentrationindepend
kill
durat
time
drug
concentr
exce
mic
infect
pathogen
site
infect
primari
determin
efficaci
macrolid
agent
prolong
postantibiot
effect
pae
gramposit
cocci
h
influenza
optim
durat
time
mic
remain
controversi
postul
pae
allow
drug
yield
maxim
efficaci
murin
thigh
infect
concentr
exceed
mic
significantli
less
dose
interv
ie
extend
pae
long
serum
halflif
proper
pharmacodynam
correl
azithromycin
may
aucmic
ratio
rather
mic
concern
rais
regard
azithromycin
propens
select
bacteria
macrolideresist
impact
communitybas
azithromycin
use
carriag
resist
pneumonia
prospect
studi
singledos
azithromycin
mgkg
given
children
trachoma
chronic
diseas
caus
chlamydia
trachomati
household
contact
children
carriag
rate
azithromycinresist
pneumonia
immedi
treatment
week
month
month
treatment
respect
select
pressur
azithromycin
may
allow
growth
transmiss
preexist
azithromycinresist
strain
one
possibl
explan
observ
relat
azithromycin
long
serum
halflif
long
durat
subinhibitori
concentr
drug
serum
auc
two
antimicrobi
one
short
long
serum
halflif
compar
mic
valu
superimpos
period
window
potenti
darwinian
select
plot
figur
antimicrobi
short
halflif
durat
time
drug
concentr
fall
mic
total
elimin
bodi
rel
short
compar
antimicrobi
longer
halflif
antimicrobi
halflif
eg
azithromycin
total
elimin
bodi
occur
halfliv
day
period
subinhibitori
concentr
drug
may
pharmacodynam
explan
aforemen
tion
observ
concept
controversi
requir
valid
futur
studi
antimicrobi
exhibit
concentrationdepend
kill
unlik
concentrationindepend
antimicrobi
agent
fluoroquinolon
kill
rapidli
concentr
appreci
mic
target
microorgan
type
kill
refer
concentrationdepend
timeindepend
kill
figur
shown
fluoroquinolon
erad
organ
best
level
time
microb
mic
higher
drug
concentr
improv
rate
extent
bacteri
kill
optim
peak
mic
ratio
obtain
bacteria
die
rapidli
consequ
period
time
bacteria
expos
drug
minim
although
peak
mic
ratio
greater
correl
optim
bactericid
activ
aucmic
ratio
better
paramet
determin
efficaci
fluoroquinolon
moder
suscept
bacteria
pneumonia
fact
fluoroquinolon
dose
fraction
studi
aucmic
ratio
better
correl
efficaci
peak
mic
ratio
data
obtain
sever
sourc
includ
anim
model
sepsi
vitro
pharmacodynam
experi
clinic
outcom
studi
indic
magnitud
aucmic
ratio
use
predict
respons
forrest
et
al
demon
fig
pharmacodynam
vivo
bacteri
kill
may
describ
function
durat
antimicrobi
drug
concentr
time
rel
mic
agent
particular
pathogen
product
pharmacokinet
paramet
drug
concentr
time
drug
exposur
dose
interv
express
auc
strate
aucmic
ratio
associ
highest
bacteri
erad
rate
treatment
infect
caus
gramneg
enter
pathogen
howev
gramposit
bacteria
appear
effect
aucmic
ratio
appreci
lower
instanc
pneumonia
vitro
model
infect
demonstr
levofloxacin
ciprofloxacin
aucmic
ratio
approxim
associ
reduct
bacteri
titer
wherea
ratio
less
associ
significantli
reduc
rate
bacteri
kill
instanc
bacteri
regrowth
similarli
lister
sander
report
levofloxacin
ciprofloxacin
auc
mic
ratio
associ
maxim
erad
pneumonia
vitro
model
infect
observ
support
data
nonneutropen
anim
model
infect
surviv
associ
aucmic
ratio
pneumococcu
rel
factor
affect
adequaci
therapeut
regimen
two
import
factor
drug
exposur
seen
patient
suscept
offend
pathogen
antiinfect
agent
select
therapi
unfortun
major
limit
type
pharmacodynam
analysi
describ
variabl
pharmacokinet
microbiolog
data
account
factor
highli
variabl
variabl
suscept
track
differ
mic
consequ
larg
collect
target
organ
give
clinician
reason
idea
distribut
suscept
drug
among
pathogen
care
often
clinician
fail
realiz
patient
take
dose
drug
particularli
oral
rout
rout
administr
may
differ
drug
exposur
instanc
preston
et
al
studi
patient
infect
receiv
levofloxacin
although
median
plasma
clearanc
approxim
lh
patient
clearanc
low
lh
wherea
other
high
lh
standard
dose
patient
would
auc
low
mghr
per
liter
wherea
other
would
auc
mghr
per
liter
differ
drug
exposur
would
therapeut
adequ
differ
mic
differ
organ
instanc
pneumococcu
target
aucmic
ratio
approxim
essenti
patient
would
adequ
coverag
dose
produc
target
aucmic
mic
high
gml
p
aeruginosa
pharmacodynam
target
substanti
fraction
patient
would
hit
target
mic
gml
greater
patient
target
aucmic
ratio
could
achiev
organ
mic
gml
less
patient
low
plasma
clearanc
rel
high
auc
would
result
patient
would
adequ
coverag
organ
higher
mic
mont
carlo
simul
way
take
variabl
seen
patient
microbiolog
data
account
choos
dose
schedul
antibiot
mont
carlo
simul
prior
knowledg
use
handl
drug
popul
patient
done
use
mean
valu
pharmacokinet
paramet
also
provid
covari
matrix
paramet
covari
matrix
provid
inform
variabl
pharmacokinet
paramet
popul
covari
one
anoth
mont
carlo
simul
program
randomli
sampl
popul
patient
describ
mean
paramet
covari
matrix
program
direct
perform
sampl
larg
number
time
eg
time
way
popul
simul
patient
creat
use
larg
number
simul
patient
accur
estim
develop
often
patient
whose
plasma
clearanc
lh
auc
dose
levofloxacin
encount
often
subject
plasma
clearanc
lh
auc
approxim
dose
encount
valu
mic
possibl
determin
frequent
therapeut
target
simul
popul
patient
attain
fda
advisori
committe
antiinfect
drug
product
found
method
present
drusano
reason
approach
octob
pharmacodynam
analysi
conduct
member
panel
h
influenza
isol
use
mont
carlo
method
describ
ambros
grasela
data
use
analysi
includ
human
pharmacokinet
data
obtain
fda
licens
trial
suscept
data
isol
collect
unit
state
analysi
jacob
et
al
oral
may
index
follow
cefixim
cefpodoxim
proxetil
amoxicillin
clavulan
high
dose
cefuroxim
axetil
amoxicillin
cefprozil
loracarbef
cefaclor
previous
discuss
pharmacokineticpharmacodynam
pkpd
paramet
defin
suscept
breakpoint
oral
antibiot
macrolid
serum
concentr
maintain
least
dose
interv
determin
use
pkpd
breakpoint
fluoroquinolon
azithromycin
pkpd
breakpoint
base
aucmic
ratio
exceed
tabl
compar
suscept
isol
pneumonia
h
influenza
catarrhali
variou
antibiot
accord
pkpd
breakpoint
panel
use
pkpd
breakpoint
prefer
nation
committe
clinic
laboratori
standard
fda
breakpoint
allow
unbias
comparison
sinus
pathogen
use
one
breakpoint
agent
current
nccl
breakpoint
agent
vari
consider
pathogen
exampl
suscept
cefprozil
breakpoint
haemophilu
pneumonia
exampl
includ
azithromycin
clarithromycin
breakpoint
respect
haemophilu
wherea
breakpoint
pneumonia
mgml
respect
addit
breakpoint
catarrhali
antimicrobi
highest
activ
isol
pneumonia
includ
amoxicillin
amoxicillinclavulan
clindamycin
gatifloxacin
levofloxacin
moxifloxacin
amoxicillinclavulan
cefixim
cefpodoxim
proxetil
gatifloxacin
levofloxacin
moxifloxacin
highest
activ
isol
h
influenza
amoxicillinclavulan
cefixim
erythromycin
clarithromycin
azithromycin
doxycyclin
gatifloxacin
levofloxacin
moxifloxacin
superb
activ
catarrhali
recommend
base
pool
therapeut
outcom
model
describ
tabl
summar
panel
antimicrobi
treatment
guidelin
adult
children
respect
multipl
factor
play
role
antimicrobi
select
process
seriou
intracrani
extrasinu
complic
associ
abr
usual
aris
result
pneumonia
infect
import
initi
therapi
adequ
cover
pneumonia
gramneg
coverag
h
influenza
catarrhali
children
ignor
howev
ration
approach
treatment
abr
consid
aforement
concern
along
logic
applic
microbiolog
pkpd
principl
select
antibiot
abr
clinician
consid
sever
diseas
rate
progress
diseas
recent
antibiot
therapi
vari
rate
resist
within
unit
state
countri
may
use
guidelin
panel
guidelin
adult
children
abr
character
sever
differ
group
patient
patient
type
includ
mild
moder
diseas
without
antibiot
therapi
previou
month
without
clinic
respons
hour
initi
therapi
term
mild
moder
diseas
reflect
degre
discomfort
patient
evidenc
symptom
complex
time
cours
diseas
healthi
patient
day
persist
anterior
posterior
rhinorrhea
fatigu
mild
diseas
differ
patient
day
nasal
congest
past
day
develop
lowgrad
elev
temperatur
increas
unilater
maxillari
frontal
tender
worsen
bend
moder
diseas
patient
howev
may
alway
neatli
categor
degre
diseas
evalu
sever
diseas
requir
clinic
judgment
gain
clinician
familiar
patient
differ
sever
diseas
impli
presenc
absenc
antimicrobi
resist
rather
terminolog
indic
tabl
recommend
antibiot
therapi
adult
abr
rel
degre
accept
possibl
failur
therapi
sever
lifethreaten
infect
without
complic
address
guidelin
prior
antibiot
use
major
risk
factor
associ
developt
continu
footnot
term
mild
moder
design
aid
clinician
antibiot
choic
differ
sever
diseas
impli
presenc
absenc
antimicrobi
resist
rather
terminolog
indic
rel
degre
accept
possibl
failur
therapi
determin
sever
diseas
rest
clinician
evalu
patient
histori
clinic
present
sever
lifethreaten
infect
without
complic
address
guidelin
prior
antibiot
therapi
within
past
week
risk
factor
infect
resist
organ
antibiot
choic
need
base
risk
factor
bacteri
efficaci
microbiolog
adequaci
mean
rang
set
calcul
pool
therapeut
outcom
model
use
suscept
data
base
us
compon
alexand
project
sentri
surveil
cdc
activ
bacteri
core
surveil
report
valu
guarante
clinic
success
failur
valu
reflect
potenti
therapeut
failur
initi
therapi
base
us
compon
alexand
project
surveil
studi
use
local
surveil
data
provid
valuabl
addit
inform
preval
resist
applic
region
chang
antibiot
therapi
made
clinician
need
take
account
limit
coverag
initi
antibiot
amoxicillin
lack
complet
h
influenza
coverag
cefuroxim
cefpodoxim
cover
penicillinresist
pneumonia
erythromycin
doxycyclin
tmpsmx
limit
coverag
h
influenza
pneumonia
amoxicillinclavulan
gatifloxacin
levofloxacin
moxifloxacin
current
best
coverag
h
influenza
pneumonia
reevalu
necessari
antibiot
recommend
day
initi
therapi
effect
pneumonia
h
influenza
addit
histori
physic
examin
cultur
andor
ct
scan
may
indic
possibl
less
common
pathogen
consid
total
daili
dose
amoxicillin
amoxicillin
compon
amoxicillinclavulan
vari
gday
lower
daili
dose
gday
appropri
mild
diseas
patient
prior
antibiot
use
higher
daili
dose
gday
may
advantag
area
high
preval
drsp
patient
moder
diseas
recent
prior
antibiot
use
greater
potenti
treatment
failur
resist
pathogen
patient
group
higher
dose
current
approv
fda
unit
state
formal
safeti
studi
publish
although
cefpodoxim
cefixim
excel
activ
h
influenza
activ
penicillinresist
pneumonia
clindamycin
provid
excel
coverag
pneumonia
activ
h
influenza
antibiot
recommend
unless
patient
allerg
blactam
effect
major
pathogen
abr
limit
bacteri
failur
possibl
lifethreaten
toxic
epiderm
necrolysi
associ
use
tmpsmx
base
vitro
spectrum
activ
combin
therapi
amoxicillin
gday
clindamycin
gramposit
coverag
plu
cefixim
gramneg
coverag
suggestedrecommend
clinic
evid
time
howev
safeti
efficaci
combin
consid
initi
fluoroquinolon
recommend
patient
allergi
intoler
recent
respond
regimen
therapi
ment
infect
antimicrobialresist
strain
risk
factor
includ
age
less
year
attend
day
care
center
risk
factor
invas
infect
includ
prior
use
resid
nurs
home
recent
hospit
hematolog
malign
seriou
comorbid
ill
immunosuppress
underli
diseas
prior
use
tmpsmx
also
identifi
risk
factor
carriag
penicillinnonsuscept
pneumonia
recent
antimicrobi
exposur
increas
risk
carriag
infect
resist
organ
antimicrobi
therapi
base
patient
histori
recent
antibiot
use
panel
guidelin
therefor
stratifi
patient
accord
antibiot
exposur
previou
week
lack
respons
therapi
hour
arbitrari
time
establish
defin
treatment
failur
clinician
monitor
pa
tabl
recommend
antibiot
therapi
children
abr
term
mild
moder
design
aid
clinician
antibiot
choic
differ
sever
diseas
impli
presenc
absenc
antimicrobi
resist
rather
terminolog
indic
rel
degre
accept
possibl
failur
therapi
determin
sever
diseas
rest
clinician
evalu
patient
histori
clinic
present
sever
lifethreaten
infect
without
complic
address
guidelin
prior
antibiot
therapi
within
past
week
risk
factor
infect
resist
organ
antibiot
choic
need
base
risk
factor
bacteri
efficaci
microbiolog
adequaci
mean
rang
set
calcul
pool
therapeut
outcom
model
see
text
use
suscept
databas
us
compon
alexand
project
sentri
surveil
cdc
activ
bacteri
core
surveil
report
valu
guarante
clinic
success
failur
valu
reflect
potenti
therapeut
failur
initi
therapi
base
us
compon
alexand
project
surveil
studi
use
local
surveil
data
provid
valuabl
addit
inform
preval
resist
applic
region
chang
antibiot
therapi
made
clinician
need
take
account
limit
coverag
initi
antibiot
amoxicillin
lack
complet
h
influenza
catarrhali
coverag
cefuroxim
cefpodoxim
cover
penicillinresist
pneumonia
erythromycin
tmpsmx
limit
coverag
h
influenza
pneumonia
amoxicillinclavulan
current
best
coverag
pneumonia
h
influenza
catarrhali
reevalu
necessari
antibiot
recommend
day
effect
pneumonia
h
influenza
catarrhali
addit
histori
physic
examin
cultur
andor
ct
scan
may
indic
possibl
less
common
pathogen
consid
dose
amoxicillin
rang
mg
mgkg
per
day
lower
dose
amoxicillin
use
initi
treatment
failur
may
due
drsp
h
influenza
catarrhali
higher
dose
schedul
give
better
drsp
coverag
amoxicillin
compon
amoxicillinclavulan
also
rang
mg
mgkg
per
day
higher
daili
dose
mgkg
per
day
may
advantag
area
high
preval
drsp
patient
moder
diseas
recent
prior
antibiot
use
greater
potenti
treatment
failur
resist
pathogen
patient
group
higher
dose
current
approv
fda
unit
state
although
cefpodoxim
proxetil
cefuroxim
axetil
cefixim
higher
activ
h
influenza
catarrhali
amoxicillin
activ
penicillinresist
pneumonia
exclud
clindamycin
activ
oral
agent
current
avail
activ
pneumonia
activ
howev
h
influenza
catarrhali
base
vitro
spectrum
activ
combin
therapi
amoxicillin
mgkg
per
day
clindamycin
gramposit
coverag
plu
cefixim
cefpodoxim
proxetil
tmpsmx
gramneg
coverag
suggestedrecommend
clinic
evid
time
howev
safeti
efficaci
combin
antibiot
recommend
unless
patient
allerg
effect
major
pathogen
abr
limit
bacteri
failur
possibl
addit
tmpsmx
associ
increas
risk
life
threaten
toxic
epiderm
necrolysi
clinician
differenti
immedi
hypersensit
reaction
less
danger
side
effect
children
immedi
hypersensit
reaction
may
need
desensit
sinu
cultur
ancillari
procedur
studi
children
type
reaction
side
effect
may
toler
one
specif
anoth
tient
respons
antibiot
therapi
may
includ
instruct
patient
call
offic
clinic
persist
worsen
symptom
current
recommend
durat
antimicrobi
treatment
abr
day
base
result
publish
studi
clinic
trial
pretreat
posttreat
sinu
aspir
perform
use
longer
shorter
cours
antimicrobi
treatment
base
result
sinu
aspir
studi
allergi
antibiot
ie
age
limit
certain
antimicrobi
eg
fluoroquinolon
may
forc
use
less
optim
antimicrobi
clinician
must
awar
potenti
treatment
failur
situat
panel
use
pool
therapeut
outcom
model
one
tool
develop
antimicrobi
guidelin
although
recent
best
data
use
model
panel
realiz
resist
rate
may
chang
time
may
vari
commun
commun
panel
therefor
revis
guidelin
resist
rate
chang
new
antibiot
introduc
addit
pool
therapeut
outcom
model
develop
michael
pool
univers
texa
medic
school
houston
avail
sinu
allergi
web
site
http
wwwallergysinusorg
clinician
may
input
local
resist
rate
obtain
optim
treatment
recommend
local
resist
data
base
pkpd
breakpoint
nccl
breakpoint
discuss
supplement
marchant
et
al
correl
vivo
potenc
variou
antimicrobi
agent
clinic
outcom
base
doubl
tap
otiti
media
studi
addit
pkpd
suscept
breakpoint
given
dose
regimen
shown
correl
bacteriolog
cure
rate
appropri
data
marchant
et
al
predict
clinic
respons
rate
given
dose
regimen
antimicrobi
agent
paramet
use
adapt
model
abr
includ
proport
patient
clinic
diagnosi
abr
posit
sinu
aspir
typic
patient
primari
care
practic
clinic
resolut
diseas
cultureneg
patient
group
typic
patient
complet
resolut
diseas
occur
group
total
patient
group
diseas
fail
resolv
occur
remain
total
patient
group
distribut
pathogen
found
cultureposit
group
spontan
resolut
rate
pathogen
vitro
suscept
major
sinus
pathogen
antimicrobi
agent
pkpd
breakpoint
base
publish
studi
maxillari
sinu
punctur
perform
patient
abr
pathogen
distribut
use
adult
pneumonia
h
influenza
catarrhali
pathogen
pathogen
distribut
children
use
pneumonia
h
influenza
catarrhali
pneumonia
pathogen
bacteri
organ
model
incorpor
higher
preval
pneumonia
children
ensur
appropri
antimicrobi
coverag
major
pathogen
spontan
resolut
rate
estim
publish
data
placebo
use
otiti
media
valu
use
model
pneumonia
h
influenza
catarrhali
pathogen
base
valu
spontan
resolut
predict
occur
adult
abr
total
patient
group
therefor
spontan
resolut
occur
untreat
adult
group
infect
plu
without
infect
adult
patient
whose
symptom
resolv
untreat
uninfect
respond
nonmicrobiolog
relat
factor
wherea
respond
untreat
bacteri
infect
howev
drug
bacteriolog
efficaci
use
diseas
theoret
resolv
adult
patient
infect
group
adult
patient
thu
theoret
diseas
resolut
rate
adult
model
depend
efficaci
treatment
vari
rate
spontan
resolut
patient
treat
antimicrobi
bacteri
efficaci
total
adult
group
limit
vari
untreat
use
agent
efficaci
hand
spontan
resolut
occur
untreat
children
bacteri
infect
group
untreat
total
pediatr
patient
group
importantli
individu
valu
variou
paramet
estim
interest
investig
could
chang
valu
use
model
calcul
result
effect
bacteriolog
clinic
outcom
next
step
calcul
resolut
diseas
base
current
suscept
data
organ
pkpd
breakpoint
agent
poor
activ
pathogen
result
resolut
rate
similar
spontan
resolut
seen
untreat
group
wherea
agent
activ
pathogen
result
higher
resolut
rate
resolut
rate
bacteri
infect
group
total
patient
group
use
mean
suscept
data
us
compon
alexand
project
sentri
surveil
report
cdc
activ
bacteri
core
surveil
report
shown
marchant
plot
figur
dataset
use
complet
mic
distribut
avail
proport
isol
inhibit
pkpd
breakpoint
could
determin
outcom
calcul
shown
marchant
plot
show
predict
bacteriolog
outcom
bacteri
infect
group
total
patient
group
marchant
plot
rel
rank
order
data
use
surveil
data
may
therefor
alter
rel
rank
order
resolut
rate
base
vitro
microbiolog
efficaci
guarante
clinic
outcom
howev
absenc
microbiolog
outcom
data
clinic
studi
agent
model
use
best
method
avail
predict
clinic
outcom
accord
marchant
plot
antibiot
place
follow
rel
rank
order
predict
efficaci
adult
patient
abr
gatifloxacin
levofloxacin
moxifloxacin
amoxicillin
clavulan
highdos
amoxicillin
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
tmpsmx
doxycyclin
clindamycin
base
gramposit
coverag
cefprozil
azithromycin
clarithromycin
erythromycin
cefaclor
loracarbef
predict
spontan
resolut
rate
untreat
adult
abr
accord
marchant
plot
antibiot
place
follow
rel
rank
order
predict
efficaci
children
bacteri
infect
amoxicillinclavulan
highdos
amoxicillin
cefpodoxim
proxetil
cefixim
base
h
influenza
catarrhali
coverag
cefuroxim
axetil
clindamycin
base
gramposit
coverag
azithromycin
clarithromycin
erythromycin
tmpsmx
cefprozil
cefaclor
loracarbef
predict
spontan
resolut
rate
untreat
children
abr
recommend
made
treatment
guidelin
take
account
major
factor
sever
diseas
use
antibiot
preced
week
rel
rank
order
agent
marchant
plot
addit
recommend
patient
improv
worsen
hour
treatment
provid
base
spectrum
activ
initi
therapi
major
sinus
pathogen
estim
likelihood
particular
pathogen
encount
treatment
failur
type
initi
therapi
use
lieu
obtain
cultur
guid
switch
therapi
hour
data
use
predict
percentag
organ
like
produc
failur
us
compon
alexand
project
reflect
mostli
patient
respond
empir
initi
antibiot
therapi
model
better
guid
switch
therapi
recommend
adult
patient
recommend
initi
therapi
adult
patient
mild
diseas
receiv
antibiot
previou
week
includ
follow
choic
tabl
amoxicillinclavulan
amoxicillin
gday
cefpo
doxim
proxetil
cefuroxim
axetil
cefprozil
may
bacteri
failur
rate
although
tmpsmx
doxycyclin
azithromycin
clarithromycin
erythromycin
may
consid
patient
allergi
bacteriolog
failur
rate
possibl
also
potenti
fatal
toxic
epiderm
necrolysi
associ
use
tmpsmx
recommend
initi
therapi
adult
mild
diseas
receiv
antibiot
previou
week
adult
moder
diseas
receiv
antibiot
previou
week
includ
follow
choic
amoxicillinclavulan
amoxicillin
gday
cefpodoxim
proxetil
cefuroxim
axetil
gatifloxacin
levofloxacin
moxifloxacin
indic
patient
allerg
intoler
recommend
initi
therapi
adult
moder
diseas
receiv
antibiot
previou
week
includ
gatifloxacin
levofloxacin
moxifloxacin
amoxicillinclavulan
combin
therapi
amoxicillin
clindamycin
gramposit
coverag
cefpodoxim
proxetil
cefixim
gramneg
coverag
recommend
switch
therapi
patient
without
improv
worsen
hour
vari
depend
like
organ
produc
clinic
failur
patient
receiv
effect
antibiot
therapi
continu
symptomat
need
evalu
ct
scan
fiberopt
endoscopi
sinu
aspir
cultur
may
necessari
amoxicillinclavulan
prescrib
area
high
incid
drsp
switch
therapi
total
gday
amoxicillin
compon
consid
although
current
approv
unit
state
recommend
pediatr
patient
recommend
initi
therapi
children
mild
diseas
receiv
antibiot
previou
week
includ
follow
tabl
amoxicillinclavulan
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefuroxim
axetil
azithromycin
clarithromycin
erythromycin
tmpsmx
recommend
patient
histori
immedi
type
hypersensit
reaction
antibiot
limit
effect
major
pathogen
abr
bacteri
failur
possibl
use
tmpsmx
associ
larg
increas
risk
lifethreaten
toxic
epiderm
necrolysi
clinician
differenti
immedi
hypersensit
reaction
less
danger
side
effect
children
immedi
hypersensit
reaction
may
need
desensit
sinu
cultur
ancillari
procedur
studi
children
type
reaction
side
effect
may
toler
one
specif
anoth
recommend
children
mild
diseas
receiv
antibiot
previou
week
children
moder
diseas
receiv
antibiot
previou
week
amoxicillinclavulan
amoxicillin
mgkg
per
day
cefpodoxim
proxetil
cefuroxim
axetil
azithromycin
clarithromycin
erythromycin
tmpsmx
recommend
patient
allerg
clindamycin
appropri
pneumonia
identifi
pathogen
moder
diseas
hand
children
receiv
antibiot
previou
week
treat
follow
altern
amoxicillinclavulan
combin
therapi
amoxicillin
clindamycin
gramposit
coverag
plu
cefpodoxim
proxetil
cefixim
gramneg
coverag
switch
therapi
patient
without
improv
worsen
hour
vari
depend
like
organ
produc
clinic
failur
patient
receiv
effect
antibiot
therapi
continu
symptomat
need
evalu
ct
scan
fiberopt
endoscopi
sinu
aspir
cultur
may
necessari
amoxicillinclavulan
prescrib
area
high
incid
drsp
switch
therapi
total
mgkg
per
day
amoxicillin
compon
consid
although
current
approv
unit
state
guidelin
develop
provid
evidencebas
recommend
diagnosi
optim
treatment
abr
base
limit
inform
avail
diseas
approach
base
mathemat
model
use
pathogen
distribut
spontan
resolut
data
pharmacodynam
deriv
suscept
valu
major
abr
pathogen
bacteriolog
outcom
predict
panel
hope
guidelin
provid
ration
approach
need
antimicrobi
therapi
bacteri
rhinosinus
reduct
use
antibiot
nonbacteri
infect
appropri
use
antibiot
bacteri
diseas
like
